Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYR1K8)

• Drug Name: S-17092-1 Drug Info
• Synonyms: NXSXRIHXEQSYEZ-KNJMJIDISA-N; S 17092; CHEMBL1086968; 176797-26-5; S-17092; s17092; SCHEMBL194654; GTPL6565; DTXSID70433003; ZINC3825778; BDBM50316818; NCGC00485216-01; S 17092, > ((2S,3aS,7aS)-1-((1R,2R)-2-phenylcyclopropanecarbonyl)octahydro-1H-indol-2-yl)(thiazolidin-3-yl)methanone; (2S,3aS,7aS)-1-(((R,R)-2-Phenylcyclopropyl)carbonyl)-2-((thiazolidin-3-yl)carbonyl)octahydro-1H-indole; [(2S,3aS,7aS)-Octahydro-1-[[(1R,2R)-2-phenylcyclopropyl]carbonyl]-1H-indol-2-yl]-3-thiazolidinyl--methanone; S-17092 (undefined isomer); (2S,3aS,7aS)-1-[(1R,2R)-2-Phenylcyclopropylcarbonyl]-2-(thiazolidin-3-ylcarbonyl)perhydroindole

Indication

Disease Entry	ICD 11	Status	REF
Cognitive impairment	6D71	Phase 1	[1]
Non-small-cell lung cancer	2C25.Y	Clinical trial	[2]

• Cross-matching ID:
  PubChem CID: 9929984
  CAS Number: CAS 176797-26-5
  TTD Drug ID: DMYR1K8

Molecule-Related Drug Atlas

Drug(s) Targeting Prolyl endopeptidase (PREP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BAICALEIN	DM4C7E6	Influenza virus infection	1E30-1E32	Phase 2	[4]
ALV-003	DMXSFA0	Coeliac disease	DA95	Phase 2	[5]
ONO-1603	DMKIZAL	Cognitive impairment	6D71	Phase 2	[6]
JTP-4819	DMI0UJS	Cognitive impairment	6D71	Discontinued in Phase 2	[7]
Z-321	DMLO2QY	Parkinson disease	8A00.0	Discontinued in Phase 1	[8]
BAICALIN	DMY1TLZ	Human immunodeficiency virus infection	1C62	Terminated	[9]
Y-29794	DMLAVES	N. A.	N. A.	Terminated	[9]
Double Oxidized Cysteine	DM6TU84	Discovery agent	N.A.	Investigative	[10]
Monothioglycerol	DMENSOZ	Discovery agent	N.A.	Investigative	[10]
Z-Pro-Prolinal	DM43O2U	Discovery agent	N.A.	Investigative	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prolyl endopeptidase (PREP)	TTNGKET	PPCE_HUMAN	Inhibitor	[3]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011104)
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6565).
• [3] Effect of S 17092, a novel prolyl endopeptidase inhibitor, on substance P and alpha-melanocyte-stimulating hormone breakdown in the rat brain. J Neurochem. 2003 Mar;84(5):919-29.
• [4] Baicalin, a prodrug able to reach the CNS, is a prolyl oligopeptidase inhibitor. Bioorg Med Chem. 2008 Aug 1;16(15):7516-24.
• [5] The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo. Clin Immunol. 2010 Mar;134(3):289-95.
• [6] ONO-1603, a potential antidementia drug, shows neuroprotective effects and increases m3-muscarinic receptor mRNA levels in differentiating rat cerebellar granule neurons. Neurosci Lett. 1996 Aug 23;214(2-3):151-4.
• [7] A novel prolyl endopeptidase inhibitor, JTP-4819, with potential for treating Alzheimer's disease. Behav Brain Res. 1997 Feb;83(1-2):147-51.
• [8] Z-321, a prolyl endopeptidase inhibitor, augments the potentiation of synaptic transmission in rat hippocampal slices. Behav Brain Res. 1997 Feb;83(1-2):213-6.
• [9] Inhibitors of prolyl oligopeptidases for the therapy of human diseases: defining diseases and inhibitors. J Med Chem. 2010 May 13;53(9):3423-38.
• [10] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [11] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.